Topp, Max S. http://orcid.org/0000-0002-0135-1051
Eradat, Herbert
Florschütz, Axel
Hochhaus, Andreas
Wrobel, Tomasz
Walewski, Jan
Knopinska-Posluszny, Wanda
Kanate, Abraham S.
Lech-Maranda, Ewa
Brunnberg, Uta
Chitra, Surya
Nielsen, Tina G.
Sellam, Gila
Shivhare, Mahesh
Lossos, Izidore S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
https://doi.org/10.1007/s00432-021-03847-5
Novel treatments in B cell non-Hodgkin’s lymphomas
https://doi.org/10.1136/bmj-2020-063439
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 31 March 2021
Accepted: 30 October 2021
First Online: 18 February 2022
Declarations
:
: H.E. reported: research funding, honoraria, or consulting fees from AbbVie, Genentech, Inc., Kite, Gilead Sciences, Takeda, Acerta, AstraZeneca, BeiGene and Juno. M.T. reported: research grants from Amgen, Gilead Sciences, Macrogenics, F. Hoffmann-La Roche Ltd, and Regeneron; consulting fees from Amgen and F. Hoffmann-La Roche Ltd; and advisory board membership for Amgen and Regeneron. T.W. reported: research grants and advisory board membership for F. Hoffmann-La Roche Ltd, Amgen, and Novartis; lecture fees from F. Hoffmann-La Roche Ltd, Novartis, and Celgene; and advisory board membership for Celgene. I.S.L. reported: advisory board membership for Seattle Genetics and Janssen Scientific. J.W. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Celgene, Takeda, Janssen-Cilag, Servier, Amgen, BMS, Incyte, and AbbVie; research funding from F. Hoffmann-La Roche Ltd, GSK/Novartis, Takeda, Janssen-Cilag, and AbbVie; lecture honoraria from F. Hoffmann-La Roche Ltd, Celgene, Takeda, Janssen-Cilag, and Servier; and conference travel support from Roche. U.B. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Gilead Sciences, Janssen, MSD, and Hexal; and travel grants from Janssen, Amgen, F. Hoffmann-La Roche Ltd, and Gilead Sciences. A.H. reported: research support by F. Hoffmann-La Roche Ltd, Novartis, BMS, Pfizer, and Incyte. E.L.M. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Gilead Sciences, Takeda, Janssen-Cilag, Amgen, Novartis, AbbVie, and Celgene; lecture honoraria from F. Hoffmann-La Roche Ltd, Janssen-Cilag, Amgen; and conference travel support from F. Hoffmann-La Roche Ltd, Janssen-Cilag, and Amgen. W.K-P. declared no disclosures to report. A.S.K reports that West Virginia University, WV, USA directly received research funding outside the submitted work. T.N., S.C., M.S. and G.S. declared employment at F. Hoffmann-La Roche Ltd/Genentech, Inc. T.N. declared stock ownership at F. Hoffmann-La Roche Ltd/Genentech, Inc.
: Qualified researchers may request access to individual patient level data through the clinical study data request platform (ExternalRef removed). Further details on Roche's criteria for eligible studies are available here: (ExternalRef removed). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (ExternalRef removed).